Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab

Hepatology Research

Volumn 44, Issue 3, 2014, Pages 354-357

  Nakano, Nobuaki ^a   Kusumoto, Shigeru ^b   Tanaka, Yasuhito ^b   Ishida, Takashi ^b   Takeuchi, Shogo ^a   Takatsuka, Yoshifusa ^a   Akinaga, Shiro ^c   Mizokami, Masashi ^d   Ueda, Ryuzo ^e   Utsunomiya, Atae ^a  

^a IMAMURA BUN IN HOSPITAL   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CC chemokine receptor 4; Hepatitis B virus; Mogamulizumab; Reactivation

Indexed keywords

CARBOPLATIN; CHEMOKINE RECEPTOR CCR4; CYCLOPHOSPHAMIDE; ENTECAVIR; ETOPOSIDE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LACTATE DEHYDROGENASE; MOGAMULIZUMAB; NEOMINOPHAGEN C; PIRARUBICIN; PREDNISOLONE; SOBUZOXANE; VINCRISTINE; VIRUS DNA;

AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CERVICAL LYMPH NODE; CERVICAL LYMPHADENOPATHY; DISEASE COURSE; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; INTRATHORACIC DRUG ADMINISTRATION; JAPANESE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA CELL; LEUKOCYTE COUNT; LYMPHADENOPATHY; LYMPHOCYTE COUNT; LYMPHOMA CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; SEROLOGY; SOUTHERN BLOTTING; T CELL LEUKEMIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR FLARE; VIRUS DNA CELL DNA INTERACTION; VIRUS REACTIVATION; WEIGHT REDUCTION;

EID: 84895092209     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12117     Document Type: Article

References (15)

1. Lok AS, Liang RH, Chiu EK etal. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188.
2. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69.
3. Hui CK, Cheung WW, Zhang HY etal. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.
4. Yeo W, Chan TC, Leung NW etal. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611.
5. Kusumoto S, Tanaka Y, Mizokami M etal. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90: 13-23.
6. Matsue K, Kimura S, Takanashi Y etal. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010; 116: 4769-4776.
7. Ishida T, Ueda R. Antibody therapy for Adult T-cell leukemia-lymphoma. Int J Hematol 2011; 94: 443-452.
8. Ishii T, Ishida T, Utsunomiya A etal. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010; 16: 1520-1531.
9. Yamamoto K, Utsunomiya A, Tobinai K etal. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010; 28: 1591-1598.
10. Ishida T, Joh T, Uike N etal. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30: 837-842.
11. Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol 2012; 47: 849-861.
12. Oketani M, Ido A, Nakayama N etal. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res 2013; 43: 97-105.
13. Oketani M, Ido A, Uto H etal. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 2012; 42: 627-636.
14. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
15. Kusumoto S, Tanaka Y, Suzuki R etal. Prospective nationwide observational study of hepatitis B virus (HBV) DNA monitoring and preemptive antiviral therapy for HBV reactivation in patients with B-cell non-Hodgkin lymphoma following rituximab containing chemotherapy: results of interim analysis. Blood 2012; 120: abstract 2641.